Read + Share
Foong KS. Corrigendum to "The IL-6 hypothesis in COVID-19: A phase 2, randomised,
double-blind, placebo-controlled study to evaluate the efficacy and safety of
free IL-6 sequestration by the monoclonal antibody sirukumab in severe and
critical COVID-19" [J Infe J Infect 2024;89:106343.
PMID: 39541804
|
 |
|
